All In Biotech

Drug Trial Radar · NCT04658862

A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder

A Phase 3, Multi-center, Randomized Study Evaluating Efficacy of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-Invasive Urothelial Carcinoma (MIBC) of the Bladder Who Are Not Receiving Radical Cystectomy

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 518 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

518

Actual

Start

Dec 7, 2020

Primary completion

Dec 30, 2026

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Dec 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.

Conditions

  • Urinary Bladder Neoplasms

Interventions

  • CetrelimabBiological

    Participants will receive intravenous Cetrelimab.

  • TAR-200Drug

    Participants will receive intravesical TAR-200.

  • CisplatinDrug

    Participants will receive cisplatin intravenously.

  • GemcitabineDrug

    Participants will receive gemcitabine intravenously.

  • Conventional radiation therapyRadiation

    Participants will receive conventional radiation therapy for bladder (64 gy).

  • Hypo-fractioned radiation therapyRadiation

    Participants will receive hypo-fractioned radiation therapy for bladder (55 gy).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time from Randomization to the First Bladder Intact Event-free Survival (BI-EFS) eventTime frame: Up to 8 years

Locations

290 sites in 25 countries. Site status is shown where the registry gives one.

  • Loma Linda Univ Faculty Medic

    Loma Linda, California

  • University of Southern California

    Los Angeles, California

  • Providence Saint John s Health Center

    Santa Monica, California

  • Stanford University Medical Center

    Stanford, California

  • The Urology Center of Colorado

    Denver, Colorado

  • Foothills Urology - Golden Off

    Golden, Colorado

  • Boca Raton Regional Hospital

    Boca Raton, Florida

  • Urological Research Network

    Hialeah, Florida

  • Memorial Healthcare System

    Pembroke Pines, Florida

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • DuPage Medical Group

    Lisle, Illinois

  • University Hospitals Seidman Cancer Center

    Ann Arbor, Michigan

  • Michigan Institute of Urology

    Troy, Michigan

  • Adult Pediatric Urology & Urogynecology, P.C

    Omaha, Nebraska

  • Garden State Urology

    Morristown, New Jersey

  • New Jersey Urology LLC

    Voorhees Township, New Jersey

  • Cardiology Clinic at Montefiore Hutchinson Complex

    The Bronx, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Vidant Urology - Greenville

    Greenville, North Carolina

  • Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center

    Winston-Salem, North Carolina

  • Wexner Medical Center at the Ohio State University

    Columbus, Ohio

  • Stephenson Cancer Center

    Oklahoma City, Oklahoma

  • MidLantic Urology

    Bala-Cynwyd, Pennsylvania

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • University of Tennessee Medical Center

    Knoxville, Tennessee

  • Houston Metro Urology

    Houston, Texas

  • University of Texas Medical Branch

    League City, Texas

  • Virginia Oncology Associates

    Norfolk, Virginia

  • Fundacion Intecnus

    Bariloche, Argentina

  • Hospital Italiano de Buenos Aires

    Buenos Aires, Argentina

  • Asociacion de Beneficencia Hospital Sirio Libanes

    Buenos Aires, Argentina

  • Instituto Medico Especializado Alexander Fleming

    Buenos Aires, Argentina

  • Centro de Urologia (CDU)

    Ciudad Automoma Buenos Aires, Argentina

  • Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica

    Córdoba, Argentina

  • Centro Urologico Profesor Bengio

    Córdoba, Argentina

  • Sanatorio Allende Cerro

    Córdoba, Argentina

  • Centro Oncologico Riojano Integral (Cori)

    La Rioja, Argentina

  • Centro de Investigacion Pergamino SA

    Pergamino, Argentina

  • CEDIC Centro de Investigaciones Clinicas

    Viedma, Argentina

  • Flinders Medical Centre

    Bedford Park, Australia

Showing 40 of 290 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.